Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

MC2 Therapeutics A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 5.4% 5.4%   Bankruptcy risk   6.2% 4.5% 6.8% 7.9% 8.6% 8.0% 17.4% 17.4%   Credit score (0-100)   39 48 35 29 28 30 9 9   Credit rating   BBB BBB BBB BB BB BB B B   Credit limit (kDKK)   0.0 0.0 0.0 -0.0 -0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   13,341 13,678 15,938 27,734 24,452 26,355 0.0 0.0   EBITDA   939 -389 1,232 1,727 1,852 1,910 0.0 0.0   EBIT   845 -605 987 1,452 1,628 1,670 0.0 0.0   Pre-tax profit (PTP)   -109,888.3 -81,272.1 -87,069.7 -25,223.0 -101,331.3 -41,851.2 0.0 0.0   Net earnings   -110,064.4 -81,401.2 -86,940.7 -25,223.0 -101,331.3 -41,851.2 0.0 0.0   Pre-tax profit without non-rec. items   -109,888 -81,272 -87,070 -25,223 -101,331 -41,851 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   84.0 767 581 554 329 206 0.0 0.0   Shareholders equity total   62,253 65,832 13,930 -21,098 -122,650 -164,534 -171,145 -171,145   Interest-bearing liabilities   41.2 27,796 7,431 67,256 157,561 191,065 171,145 171,145   Balance sheet total (assets)   74,370 106,610 36,145 51,603 38,592 30,589 0.0 0.0   Net Debt   -10,717 1,154 -374 65,790 156,753 190,139 171,145 171,145     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   13,341 13,678 15,938 27,734 24,452 26,355 0.0 0.0   Gross profit growth   29.9% 2.5% 16.5% 74.0% -11.8% 7.8% -100.0% 0.0%   Employees   10 0 12 19 16 15 0 0   Employee growth %   25.0% -100.0% 0.0% 58.3% -15.8% -6.3% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   74,370 106,610 36,145 51,603 38,592 30,589 0 0   Balance sheet change%   57.6% 43.4% -66.1% 42.8% -25.2% -20.7% -100.0% 0.0%   Added value   938.8 -389.2 1,232.1 1,727.4 1,903.1 1,910.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -369 437 -461 -330 -449 -364 -206 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 -1.0 1.0 2.0 3.0 4.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   6.3% -4.4% 6.2% 5.2% 6.7% 6.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -180.7% -89.7% -118.3% -40.5% -79.5% -12.7% 0.0% 0.0%   ROI %   -195.0% -92.9% -126.2% -44.9% -82.8% -13.0% 0.0% 0.0%   ROE %   -236.4% -127.1% -218.0% -77.0% -224.7% -121.0% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   83.7% 61.8% 38.5% -29.0% -76.1% -84.3% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -1,141.7% -296.5% -30.3% 3,808.6% 8,462.7% 9,953.4% 0.0% 0.0%   Gearing %   0.1% 42.2% 53.3% -318.8% -128.5% -116.1% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   183.4% 0.6% 14.9% 8.5% 7.4% 11.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   27.3 3.4 3.0 0.1 3.0 3.9 0.0 0.0   Current Ratio   27.3 3.4 3.0 0.1 3.0 3.9 0.0 0.0   Cash and cash equivalent   10,758.7 26,641.7 7,804.7 1,465.8 807.7 926.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   71,370.4 74,567.8 23,598.1 -48,308.4 8,208.2 13,459.8 -85,572.7 -85,572.7   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   94 0 103 91 119 127 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   94 0 103 91 116 127 0 0   EBIT / employee   84 0 82 76 102 111 0 0   Net earnings / employee   -11,006 0 -7,245 -1,328 -6,333 -2,790 0 0